Kardigan, Inc.

424B4 priced

Price $16.00 · 25,000,000 shares · Gross proceeds $400,000,000

EFFECT effective

CERT inactive

8-A12B effective

S-1/A amended

Range $14.00 to $16.00 · 23,333,334 shares

Kardigan, Inc. filed an S-1/A registration statement for its initial public offering (IPO), detailing the issuance of common stock shares. Key elements include a 1.5928-to-one stock split effective June 9, 2026, conversion of redeemable convertible preferred stock into 47,764,024 shares of common stock, and reserved shares for the 2026 Stock Option and Incentive Plan (10,620,000 shares) and 2026 Employee Stock Purchase Plan (1,180,000 shares). The filing assumes no exercise of options/warrants and no purchases by insiders. Financials show significant losses, with net losses of $56.1M for Q1 2026 and $191.9M for 2025.

S-1 filed

Kardigan, Inc. is a clinical-stage biopharmaceutical company with significant financial losses, seeking to raise capital through its IPO. The filing outlines pro forma adjustments for a reverse stock split, conversion of preferred stock to common, and potential offering proceeds. The company has no revenue and relies on ongoing research and development for its lead product candidates: Danicamtiv, Ataciguat, and Tonlamarsen.

DRS/A amended

DRS filed